Inclusion Criteria:  Adults aged ≥18 at the date of signing informed consent which is defined as the beginning of the Screening Period. An established diagnosis of ATTR cardiomyopathy as defined by protocol. Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures. An understanding, ability, and willingness to fully comply with study procedures and restrictions. Currently a patient at a study site (NAC).  Exclusion Criteria:  An inability to have or use BodyTrace device scales at usual residence (for example no mobile network cellular signal) On dialysis or end-stage renal failure (eGFR <25mL/min) Serum albumin <20g/dL or other non-hypervolaemia cause of tissue oedema (e.g. protein-losing enteropathy, nephrotic syndrome) Use of greater than 2 oral diuretics (e.g. on maximum oral diuretic therapy)